结肠直肠癌难题:m6A修饰及其与抗药性复杂关系
Mengxiang Yang1, Zhihui Dai1,2, Yuejun Han1
1Department of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, 321000 Jinhua, Zhejiang, China.
在结直肠癌 (CRC) 的发展和治疗耐药性方面,N6-甲基氨酸 (m6A) RNA 修饰至关重要. 理解m6A失调为CRC患者提供了新的治疗策略.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 结肠直肠癌 (CRC) 的发病率和死亡率在全球范围内不断上升.
- N6-甲基氨酸 (m6A) 是最丰富的内部RNA修饰,在转录后调节基因表达.
- 失调的m6A越来越多地与CRC进展和治疗失败有关.
研究的目的:
- 审查m6A生物发生和调节机制.
- 讨论m6A失调在CRC病变发生,转移和治疗耐药性的作用.
- 要突出m6A对抗化疗,向疗法和免疫疗法的影响.
主要方法:
- 在真核生物中对m6A修饰的文献综述.
- 在CRC中分析m6A相关因素.
- 检查m6A在调解治疗耐药性的作用.
主要成果:
- m6A 修改是通过编写器,擦拭器和阅读器动态调节的.
- 异常的m6A模式与CRC的发展和转移有关.
- m6A在调解对各种CRC疗法的耐药性方面发挥着重要作用.
结论:
- m6A失调是CRC病变和治疗耐药性的关键因素.
- 针对m6A途径为新型CRC疗法提供了一个有希望的途径.
- 对m6A的进一步研究对于开发有效的CRC治疗策略至关重要.
更多相关视频
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
相关概念视频
Treatment Resistant Cancers
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Mismatch Repair
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
